MA54382A - Utilisation d'un extrait de cocculus hirsutus pour le traitement de la dengue - Google Patents

Utilisation d'un extrait de cocculus hirsutus pour le traitement de la dengue

Info

Publication number
MA54382A
MA54382A MA054382A MA54382A MA54382A MA 54382 A MA54382 A MA 54382A MA 054382 A MA054382 A MA 054382A MA 54382 A MA54382 A MA 54382A MA 54382 A MA54382 A MA 54382A
Authority
MA
Morocco
Prior art keywords
fue
dengue
extract
treatment
cocculus hirsutus
Prior art date
Application number
MA054382A
Other languages
English (en)
Inventor
Saravanan A
Upasana Arora
Navin Khanna
Mudgal Kothekar
Sumit Madan
Kaushal Nayyar
Srinivas Palla
Ankur Poddar
Mohan Prasad
Rahul Shukla
Ruchi Sood
Original Assignee
Dept Of Biotechnology India
Int Centre For Genetic Engineering And Biotechnology
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dept Of Biotechnology India, Int Centre For Genetic Engineering And Biotechnology, Sun Pharmaceutical Ind Ltd filed Critical Dept Of Biotechnology India
Publication of MA54382A publication Critical patent/MA54382A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/59Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054382A 2018-12-07 2019-12-09 Utilisation d'un extrait de cocculus hirsutus pour le traitement de la dengue MA54382A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201821046412 2018-12-07

Publications (1)

Publication Number Publication Date
MA54382A true MA54382A (fr) 2021-10-13

Family

ID=68919759

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054382A MA54382A (fr) 2018-12-07 2019-12-09 Utilisation d'un extrait de cocculus hirsutus pour le traitement de la dengue

Country Status (9)

Country Link
US (1) US20220023372A1 (fr)
EP (1) EP3890762A1 (fr)
CN (1) CN113710261A (fr)
BR (1) BR112021010952A2 (fr)
MA (1) MA54382A (fr)
MX (1) MX2021006654A (fr)
PH (1) PH12021551332A1 (fr)
SG (1) SG11202105991TA (fr)
WO (1) WO2020115723A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202207960A (zh) * 2020-08-14 2022-03-01 印度商太陽製藥工業有限公司 硬毛木防己組成物及其在病毒感染中的用途
WO2022084908A1 (fr) * 2020-10-21 2022-04-28 Sun Pharmaceutical Industries Limited Compositions d'inhibition du virus sras-cov-2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400495T3 (es) * 2009-01-23 2013-04-10 Ranbaxy Laboratories Limited Actividad contra el dengue de extractos de Cissampelos pareira
WO2017103688A1 (fr) * 2015-12-17 2017-06-22 Sun Pharmaceutical Industries Limited Utilisation d'extraits de cissampelos pareira pour le traitement de la dengue

Also Published As

Publication number Publication date
BR112021010952A2 (pt) 2021-08-24
MX2021006654A (es) 2021-09-08
US20220023372A1 (en) 2022-01-27
WO2020115723A1 (fr) 2020-06-11
PH12021551332A1 (en) 2022-04-25
SG11202105991TA (en) 2021-07-29
CN113710261A (zh) 2021-11-26
EP3890762A1 (fr) 2021-10-13

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
EP3411504A4 (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3645039A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
EP3801578A4 (fr) Méthodes et compositions pour le traitement de c. difficile
EP3434291A4 (fr) Composition pour le traitement d'un disque intervertébral
EP3784260A4 (fr) Compositions pour le traitement d'affections cutanées
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3790563A4 (fr) Compositions permettant le traitement d'affections cutanées
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3766497A4 (fr) Médicament pour le traitement de la toux
FR3079749B1 (fr) Utilisation d'un peptide pour un traitement de l'epiderme
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3877402A4 (fr) Traitement combiné pour l'hypertension résistante
MA46086A (fr) Schéma posologique pour le traitement de tumeurs solides
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose